MX2020002934A - Variantes de anticuerpos. - Google Patents

Variantes de anticuerpos.

Info

Publication number
MX2020002934A
MX2020002934A MX2020002934A MX2020002934A MX2020002934A MX 2020002934 A MX2020002934 A MX 2020002934A MX 2020002934 A MX2020002934 A MX 2020002934A MX 2020002934 A MX2020002934 A MX 2020002934A MX 2020002934 A MX2020002934 A MX 2020002934A
Authority
MX
Mexico
Prior art keywords
antibody variants
antibodies
tnfî
bind
modified
Prior art date
Application number
MX2020002934A
Other languages
English (en)
Inventor
Esther Maria Furrer
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of MX2020002934A publication Critical patent/MX2020002934A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos que se unen a TNFa y comprenden una región Fc modificada. Los anticuerpos de la invención tienen una resistencia mejorada contra la degradación proteolítica y buenas funciones efectoras o propiedades farmacocinéticas.
MX2020002934A 2017-09-19 2018-09-11 Variantes de anticuerpos. MX2020002934A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17191987.1A EP3456736B1 (en) 2017-09-19 2017-09-19 Antibody variants
PCT/EP2018/074525 WO2019057567A1 (en) 2017-09-19 2018-09-11 ANTIBODY VARIANTS

Publications (1)

Publication Number Publication Date
MX2020002934A true MX2020002934A (es) 2020-07-22

Family

ID=59923273

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002934A MX2020002934A (es) 2017-09-19 2018-09-11 Variantes de anticuerpos.

Country Status (20)

Country Link
US (2) US11472872B2 (es)
EP (2) EP3456736B1 (es)
JP (2) JP7370965B2 (es)
KR (1) KR20200052305A (es)
CN (2) CN111094344B (es)
AR (1) AR113117A1 (es)
CA (1) CA3074250A1 (es)
CY (1) CY1124244T1 (es)
DK (1) DK3456736T3 (es)
ES (1) ES2873650T3 (es)
HR (1) HRP20210823T1 (es)
HU (1) HUE054261T2 (es)
LT (1) LT3456736T (es)
MX (1) MX2020002934A (es)
PL (1) PL3456736T3 (es)
PT (1) PT3456736T (es)
RS (1) RS61883B1 (es)
SI (1) SI3456736T1 (es)
TW (1) TWI829648B (es)
WO (1) WO2019057567A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3456736T (lt) * 2017-09-19 2021-06-10 Tillotts Pharma Ag Antikūnų variantai
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
WO2023109928A1 (zh) * 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2577329A1 (en) * 2004-08-16 2006-03-02 Medimmune, Inc. Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
ATE499385T1 (de) 2004-12-29 2011-03-15 Yuhan Corp Tumornekrosefaktor-alpha spezifische humanisierte antikörper
AU2005323025A1 (en) 2004-12-31 2006-07-13 Biogen Idec Ma Inc. Polypeptides that bind BR3 and uses thereof
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
PL2654780T3 (pl) 2010-12-23 2017-07-31 Janssen Biotech, Inc Aktywne mutanty przeciwciała fc odporne na proteazy
KR20160007478A (ko) 2013-01-10 2016-01-20 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
JP7155008B2 (ja) 2016-03-14 2022-10-18 ウニヴァーシテテット イ オスロ 変化されたＦｃＲｎを有する改変された免疫グロブリン
DK3219726T3 (da) 2016-03-17 2020-12-07 Tillotts Pharma Ag Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf
LT3456736T (lt) * 2017-09-19 2021-06-10 Tillotts Pharma Ag Antikūnų variantai

Also Published As

Publication number Publication date
HUE054261T2 (hu) 2021-08-30
US11472872B2 (en) 2022-10-18
US20200277367A1 (en) 2020-09-03
JP2024010000A (ja) 2024-01-23
ES2873650T3 (es) 2021-11-03
LT3456736T (lt) 2021-06-10
DK3456736T3 (da) 2021-05-03
US20230295288A1 (en) 2023-09-21
TW201915020A (zh) 2019-04-16
CY1124244T1 (el) 2022-07-22
PL3456736T3 (pl) 2021-09-13
RS61883B1 (sr) 2021-06-30
JP2020533996A (ja) 2020-11-26
CN111094344A (zh) 2020-05-01
CN118146386A (zh) 2024-06-07
EP3456736B1 (en) 2021-04-07
CA3074250A1 (en) 2019-03-28
AR113117A1 (es) 2020-01-29
TWI829648B (zh) 2024-01-21
SI3456736T1 (sl) 2021-06-30
WO2019057567A1 (en) 2019-03-28
HRP20210823T1 (hr) 2021-06-25
EP3684809A1 (en) 2020-07-29
JP7370965B2 (ja) 2023-10-30
EP3456736A1 (en) 2019-03-20
CN111094344B (zh) 2024-03-19
KR20200052305A (ko) 2020-05-14
PT3456736T (pt) 2021-05-28

Similar Documents

Publication Publication Date Title
MX2020006322A (es) Proteinas de fusion il-2 fc modificadas.
WO2017120523A3 (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG10201909716RA (en) Modified j-chain
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
WO2015168643A3 (en) Compositions and methods related to engineered fc constructs
MX2015012872A (es) Anticuerpos anti-tau y metodos de uso.
EA201992756A3 (ru) Антитела против cd48 и их конъюгаты
NZ756224A (en) Polypeptide variants and uses thereof
PH12020550930A1 (en) Human igg fc domain variants with improved effector function
WO2017075173A3 (en) Anti-factor d antibodies and conjugates
WO2017006052A3 (fr) UTILISATION DE FRAGMENTS Fc MODIFIÉS EN IMMUNOTHÉRAPIE
MX2020002934A (es) Variantes de anticuerpos.
PH12014501818A1 (en) Pseudomonas aeruginosa pcrv binding single variable domain antibodies
IL268601A (en) Antibodies against factor D and their uses
IL277573A (en) Antibody conjugates of cMET monoclonal binding agents and uses thereof
SA519401424B1 (ar) Cmet عوامل ربط أحادية النسيلة، مترافقات عقار منها واستخداماتها
PH12020500473A1 (en) Antibody variants
WO2015117057A3 (en) Protein m related immunoglobulin-binding polypeptides
MX2020002942A (es) Variantes de anticuerpos.
EP4071167A4 (en) FC REGION OF ANTIBODIES WITH ENHANCED AFFINITY TO FC?RIIB
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.
EA201991088A1 (ru) Связывающие пептиды